opc 21268 has been researched along with transforming growth factor beta in 1 studies
| Studies (opc 21268) | Trials (opc 21268) | Recent Studies (post-2010) (opc 21268) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 133 | 3 | 6 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M; Makino, H; Mimura, Y; Ogura, T; Oishi, T; Otsuka, F; Yamauchi, T | 1 |
1 other study(ies) available for opc 21268 and transforming growth factor beta
| Article | Year |
|---|---|
Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats.
Topics: Acetylglucosaminidase; Animals; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Growth Substances; Heart Rate; Hypertension; Kidney Glomerulus; Organ Size; Piperidines; Platelet-Derived Growth Factor; Polymerase Chain Reaction; Proliferating Cell Nuclear Antigen; Proteinuria; Quinolones; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger; Sodium; Transforming Growth Factor beta; Urine | 1997 |